Vaxart to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart” or the “Company”) (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced today announced that Wouter Latour, MD, chief executive officer of Vaxart is scheduled to present at the Jefferies Virtual Healthcare Conference on Thursday, June 4, 2020 at 2:00 p.m. Eastern Time.
Jefferies Virtual Healthcare Conference
Date: | Thursday, June 4th, 2020 | ||
Time: | 2:00 pm Eastern Time | ||
Format: | Presentation |
About Jefferies Virtual Healthcare Conference
The format will include video & audio company presentations, interactive panels, and 1x1 meetings conducted via organized conference calls. This virtual gathering of over 400 public &
private healthcare companies and 2,500 leading executives, institutional investors, private equity investors & VCs will address near- and long-term investment opportunities and discuss the
current mechanisms driving healthcare in the U.S. and internationally.
For further information, please visit: www.Jefferies.com/Conferences
About Vaxart
Lesen Sie auch
Vaxart is a clinical-stage biotechnology company primarily focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform. Vaxart’s vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines and have the potential to significantly increase vaccination rates. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (“RSV”), as well as a therapeutic vaccine for human papillomavirus (“HPV”). For more information, please visit www.vaxart.com.